je.st
news
Tag: cell
OpenBTS Development Cell Network serves test labs, universities.
2014-06-02 14:31:02| Industrial Newsroom - All News for Today
Range Networks Professional Development Kit facilitates experiments with OpenBTS™ or simulation of small, 2.5G cellular voice and data networks. Enabling test network setup and accelerating call initiation, Linux-based system combines access and core functions while allowing hands-on testing and development of applications. Base station comes with commercial release of OpenBTS, is fully operational out-of-the-box, and includes Asterisk softswitch, SIP authentication server, and SMS server. This story is related to the following:Test and Measuring InstrumentsSearch for suppliers of: Prototyping Systems
Tags: development
test
network
cell
Disposable Cell Strainers remove junk from FLOW and FACS samples.
2014-06-02 14:31:02| Industrial Newsroom - All News for Today
Accelerating efficient filtering while minimizing sample loss and reducing risk of cytometer clogs, Flowmi™ Cell Strainers help researchers process volume samples <1,000 µL for Flow Cytometer and Fluorescence-Assisted Cell Sorting analysis. Sterile products, available in 40 µm porosity, can be used with 1,000 µL pipette tips. No special equipment is required for use; operators press-fit Flowmi onto pipette tip containing sample and depress plunger to dispense liquid through strainer. This story is related to the following:Strainers
Tags: remove
cell
flow
samples
First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
cell
presentation
First real-time movies of the light-to-current conversion in an organic solar cell
2014-05-31 08:32:00| Climate Ark Climate Change & Global Warming Newsfeed
ScienceDaily: Photovoltaic cells directly convert sun light into electricity and hence are key technological devices to meet one of the challenges that humankind has to face in this century: a sustainable and clean production of renewable energy. Organic solar cells, using polymeric materials to capture sun light, have particularly favorable properties. They are low-cost, light-weight and flexible, and their color can be adapted by varying the material composition. Such solar cells typically consist of nanostructured...
Tags: movies
cell
conversion
organic
Cell Therapeutics, Inc. Announces Change Of Name To
2014-05-31 04:35:27| Biotech - Topix.net
"From the beginning, CTI has looked at potential therapies from the patient's perspective to address both the clinical need and the impact treatment can have on a patient's life.
Tags: to
change
cell
announces
Sites : [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] next »